Αποτελέσματα Αναζήτησης
Antiarrhythmic infusions for stable wide-QRS tachycardia procainamide IV dose: 20–50 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increases > 50% or maximum dose 17 mg/kg given. Maintenance infusion: 1–4 mg/min. Avoid if prolonged QT or CHF.
8 Μαΐ 2023 · Procainamide is a medication used to manage and treat ventricular arrhythmias, supraventricular arrhythmias, atrial flutter, atrial fibrillation, AV nodal re-entrant tachycardia, and Wolf-Parkinson-White syndrome. It is a Class 1A antiarrhythmic agent.
3 Σεπ 2024 · Note: Not recommended for use in ongoing ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) due to prolonged administration time and uncertain efficacy. Follow with maintenance dose as continuous infusion.
Procainamide IV dose: . •20-50 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increased > 50%, or maximum dose 17mg/kg given. •Maintenance infusion: 1-4 mg/min. Avoid if prolonged QT or CHF.
First dose: 6 mg rapid IV push; follow with NS flush. Second dose: 12 mg if required. Antiarrhythmic Infusions for Stable Wide-QRS Tachycardia Procainamide IV dose: 20-50 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increases >50%, or maximum dose 17 mg/kg given.
The mean dose of procainamide was 1207 ± 487 mg/day. Procainamide therapy significantly decreased ICD interventions (median 5 [0–22.5] vs 15.5 [3–32.25], P < .05). Procainamide also decreased the total number of VT/VF episodes (median 5.5 [0.75–30] vs 19 [7.5–30], P < .05). Only 3 patients (8.8%) presented severe side effects (dyspnea ...
1 Αυγ 2018 · S6-5 The administration of procainamide in out-of-hospital cardiac arrest due to VF or pulseless VT has been associated with more shocks, more pharmacologic interventions, longer resuscitation times, and lower survival.
